ArticleDiscover oncology2026
Comprehensive analysis of PANoptosis-related molecular subtypes and prognostic model development of clear cell renal cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) exhibits strong heterogeneity and variable therapeutic responses. PANoptosis, an integrated form of inflammatory programmed cell death, may influence tumor immunity and prognosis, yet its role in ccRCC remains unclear.
methodsMulti-omics data from TCGA database were analyzed to characterize PANoptosis-related genes (PRG), define molecular and gene subtypes, and construct a prognostic PRG score using Cox and LASSO regression. Immune infiltration, drug sensitivity, and predicted immunotherapy response were evaluated. Single-cell RNA sequencing analysis was used to map PRG expression across cell populations. In vitro experiments were performed to validate RBCK1 function in ccRCC.
results14 PRG showed marked CNV alterations and differential expression. Three PRG molecular subtypes displayed distinct survival outcomes and immune landscapes. A three-gene PRG score (RIPK1, PYCARD, RBCK1) independently stratified prognosis and correlated with immune infiltration, mutation burden, and therapy sensitivity. Lower scores predicted better immunotherapy response and higher drug sensitivity. Single-cell analysis revealed broad PRG expression across macrophages, epithelial cells, endothelial cells, and stem-like cells. RBCK1 was significantly upregulated in ccRCC and promoted proliferation and migration, while its knockdown inhibited tumor cell growth.
conclusionsWe delineated the PANoptosis landscape in ccRCC and developed a robust PRG score with strong prognostic and immunological relevance. RBCK1 functions as a key oncogenic regulator and potential therapeutic target. These findings offer a valuable framework for precision risk assessment and treatment optimization in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.